Cargando…
Evidence that complement and coagulation proteins are mediating the clinical response to omega-3 fatty acids: A mass spectrometry-based investigation in subjects at clinical high-risk for psychosis
Preliminary evidence indicates beneficial effects of omega-3 polyunsaturated fatty acids (PUFAs) in early psychosis. The present study investigates the molecular mechanism of omega-3 PUFA-associated therapeutic effects in clinical high-risk (CHR) participants. Plasma samples of 126 CHR psychosis par...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9616837/ https://www.ncbi.nlm.nih.gov/pubmed/36307392 http://dx.doi.org/10.1038/s41398-022-02217-0 |
_version_ | 1784820727720968192 |
---|---|
author | Susai, Subash Raj Healy, Colm Mongan, David Heurich, Meike Byrne, Jonah F. Cannon, Mary Cagney, Gerard Wynne, Kieran Markulev, Connie Schäfer, Miriam R. Berger, Maximus Mossaheb, Nilufar Schlögelhofer, Monika Smesny, Stefan Hickie, Ian B. Berger, Gregor E. Chen, Eric Y. H. de Haan, Lieuwe Nieman, Dorien H. Nordentoft, Merete Riecher-Rössler, Anita Verma, Swapna Street, Rebekah Thompson, Andrew Yung, Alison Ruth Nelson, Barnaby McGorry, Patrick D. Föcking, Melanie Amminger, G. Paul Cotter, David |
author_facet | Susai, Subash Raj Healy, Colm Mongan, David Heurich, Meike Byrne, Jonah F. Cannon, Mary Cagney, Gerard Wynne, Kieran Markulev, Connie Schäfer, Miriam R. Berger, Maximus Mossaheb, Nilufar Schlögelhofer, Monika Smesny, Stefan Hickie, Ian B. Berger, Gregor E. Chen, Eric Y. H. de Haan, Lieuwe Nieman, Dorien H. Nordentoft, Merete Riecher-Rössler, Anita Verma, Swapna Street, Rebekah Thompson, Andrew Yung, Alison Ruth Nelson, Barnaby McGorry, Patrick D. Föcking, Melanie Amminger, G. Paul Cotter, David |
author_sort | Susai, Subash Raj |
collection | PubMed |
description | Preliminary evidence indicates beneficial effects of omega-3 polyunsaturated fatty acids (PUFAs) in early psychosis. The present study investigates the molecular mechanism of omega-3 PUFA-associated therapeutic effects in clinical high-risk (CHR) participants. Plasma samples of 126 CHR psychosis participants at baseline and 6-months follow-up were included. Plasma protein levels were quantified using mass spectrometry and erythrocyte omega-3 PUFA levels were quantified using gas chromatography. We examined the relationship between change in polyunsaturated PUFAs (between baseline and 6-month follow-up) and follow-up plasma proteins. Using mediation analysis, we investigated whether plasma proteins mediated the relationship between change in omega-3 PUFAs and clinical outcomes. A 6-months change in omega-3 PUFAs was associated with 24 plasma proteins at follow-up. Pathway analysis revealed the complement and coagulation pathway as the main biological pathway to be associated with change in omega-3 PUFAs. Moreover, complement and coagulation pathway proteins significantly mediated the relationship between change in omega-3 PUFAs and clinical outcome at follow-up. The inflammatory protein complement C5 and protein S100A9 negatively mediated the relationship between change in omega-3 PUFAs and positive symptom severity, while C5 positively mediated the relationship between change in omega-3 and functional outcome. The relationship between change in omega-3 PUFAs and cognition was positively mediated through coagulation factor V and complement protein C1QB. Our findings provide evidence for a longitudinal association of omega-3 PUFAs with complement and coagulation protein changes in the blood. Further, the results suggest that an increase in omega-3 PUFAs decreases symptom severity and improves cognition in the CHR state through modulating effects of complement and coagulation proteins. |
format | Online Article Text |
id | pubmed-9616837 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-96168372022-10-30 Evidence that complement and coagulation proteins are mediating the clinical response to omega-3 fatty acids: A mass spectrometry-based investigation in subjects at clinical high-risk for psychosis Susai, Subash Raj Healy, Colm Mongan, David Heurich, Meike Byrne, Jonah F. Cannon, Mary Cagney, Gerard Wynne, Kieran Markulev, Connie Schäfer, Miriam R. Berger, Maximus Mossaheb, Nilufar Schlögelhofer, Monika Smesny, Stefan Hickie, Ian B. Berger, Gregor E. Chen, Eric Y. H. de Haan, Lieuwe Nieman, Dorien H. Nordentoft, Merete Riecher-Rössler, Anita Verma, Swapna Street, Rebekah Thompson, Andrew Yung, Alison Ruth Nelson, Barnaby McGorry, Patrick D. Föcking, Melanie Amminger, G. Paul Cotter, David Transl Psychiatry Article Preliminary evidence indicates beneficial effects of omega-3 polyunsaturated fatty acids (PUFAs) in early psychosis. The present study investigates the molecular mechanism of omega-3 PUFA-associated therapeutic effects in clinical high-risk (CHR) participants. Plasma samples of 126 CHR psychosis participants at baseline and 6-months follow-up were included. Plasma protein levels were quantified using mass spectrometry and erythrocyte omega-3 PUFA levels were quantified using gas chromatography. We examined the relationship between change in polyunsaturated PUFAs (between baseline and 6-month follow-up) and follow-up plasma proteins. Using mediation analysis, we investigated whether plasma proteins mediated the relationship between change in omega-3 PUFAs and clinical outcomes. A 6-months change in omega-3 PUFAs was associated with 24 plasma proteins at follow-up. Pathway analysis revealed the complement and coagulation pathway as the main biological pathway to be associated with change in omega-3 PUFAs. Moreover, complement and coagulation pathway proteins significantly mediated the relationship between change in omega-3 PUFAs and clinical outcome at follow-up. The inflammatory protein complement C5 and protein S100A9 negatively mediated the relationship between change in omega-3 PUFAs and positive symptom severity, while C5 positively mediated the relationship between change in omega-3 and functional outcome. The relationship between change in omega-3 PUFAs and cognition was positively mediated through coagulation factor V and complement protein C1QB. Our findings provide evidence for a longitudinal association of omega-3 PUFAs with complement and coagulation protein changes in the blood. Further, the results suggest that an increase in omega-3 PUFAs decreases symptom severity and improves cognition in the CHR state through modulating effects of complement and coagulation proteins. Nature Publishing Group UK 2022-10-28 /pmc/articles/PMC9616837/ /pubmed/36307392 http://dx.doi.org/10.1038/s41398-022-02217-0 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Article Susai, Subash Raj Healy, Colm Mongan, David Heurich, Meike Byrne, Jonah F. Cannon, Mary Cagney, Gerard Wynne, Kieran Markulev, Connie Schäfer, Miriam R. Berger, Maximus Mossaheb, Nilufar Schlögelhofer, Monika Smesny, Stefan Hickie, Ian B. Berger, Gregor E. Chen, Eric Y. H. de Haan, Lieuwe Nieman, Dorien H. Nordentoft, Merete Riecher-Rössler, Anita Verma, Swapna Street, Rebekah Thompson, Andrew Yung, Alison Ruth Nelson, Barnaby McGorry, Patrick D. Föcking, Melanie Amminger, G. Paul Cotter, David Evidence that complement and coagulation proteins are mediating the clinical response to omega-3 fatty acids: A mass spectrometry-based investigation in subjects at clinical high-risk for psychosis |
title | Evidence that complement and coagulation proteins are mediating the clinical response to omega-3 fatty acids: A mass spectrometry-based investigation in subjects at clinical high-risk for psychosis |
title_full | Evidence that complement and coagulation proteins are mediating the clinical response to omega-3 fatty acids: A mass spectrometry-based investigation in subjects at clinical high-risk for psychosis |
title_fullStr | Evidence that complement and coagulation proteins are mediating the clinical response to omega-3 fatty acids: A mass spectrometry-based investigation in subjects at clinical high-risk for psychosis |
title_full_unstemmed | Evidence that complement and coagulation proteins are mediating the clinical response to omega-3 fatty acids: A mass spectrometry-based investigation in subjects at clinical high-risk for psychosis |
title_short | Evidence that complement and coagulation proteins are mediating the clinical response to omega-3 fatty acids: A mass spectrometry-based investigation in subjects at clinical high-risk for psychosis |
title_sort | evidence that complement and coagulation proteins are mediating the clinical response to omega-3 fatty acids: a mass spectrometry-based investigation in subjects at clinical high-risk for psychosis |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9616837/ https://www.ncbi.nlm.nih.gov/pubmed/36307392 http://dx.doi.org/10.1038/s41398-022-02217-0 |
work_keys_str_mv | AT susaisubashraj evidencethatcomplementandcoagulationproteinsaremediatingtheclinicalresponsetoomega3fattyacidsamassspectrometrybasedinvestigationinsubjectsatclinicalhighriskforpsychosis AT healycolm evidencethatcomplementandcoagulationproteinsaremediatingtheclinicalresponsetoomega3fattyacidsamassspectrometrybasedinvestigationinsubjectsatclinicalhighriskforpsychosis AT mongandavid evidencethatcomplementandcoagulationproteinsaremediatingtheclinicalresponsetoomega3fattyacidsamassspectrometrybasedinvestigationinsubjectsatclinicalhighriskforpsychosis AT heurichmeike evidencethatcomplementandcoagulationproteinsaremediatingtheclinicalresponsetoomega3fattyacidsamassspectrometrybasedinvestigationinsubjectsatclinicalhighriskforpsychosis AT byrnejonahf evidencethatcomplementandcoagulationproteinsaremediatingtheclinicalresponsetoomega3fattyacidsamassspectrometrybasedinvestigationinsubjectsatclinicalhighriskforpsychosis AT cannonmary evidencethatcomplementandcoagulationproteinsaremediatingtheclinicalresponsetoomega3fattyacidsamassspectrometrybasedinvestigationinsubjectsatclinicalhighriskforpsychosis AT cagneygerard evidencethatcomplementandcoagulationproteinsaremediatingtheclinicalresponsetoomega3fattyacidsamassspectrometrybasedinvestigationinsubjectsatclinicalhighriskforpsychosis AT wynnekieran evidencethatcomplementandcoagulationproteinsaremediatingtheclinicalresponsetoomega3fattyacidsamassspectrometrybasedinvestigationinsubjectsatclinicalhighriskforpsychosis AT markulevconnie evidencethatcomplementandcoagulationproteinsaremediatingtheclinicalresponsetoomega3fattyacidsamassspectrometrybasedinvestigationinsubjectsatclinicalhighriskforpsychosis AT schafermiriamr evidencethatcomplementandcoagulationproteinsaremediatingtheclinicalresponsetoomega3fattyacidsamassspectrometrybasedinvestigationinsubjectsatclinicalhighriskforpsychosis AT bergermaximus evidencethatcomplementandcoagulationproteinsaremediatingtheclinicalresponsetoomega3fattyacidsamassspectrometrybasedinvestigationinsubjectsatclinicalhighriskforpsychosis AT mossahebnilufar evidencethatcomplementandcoagulationproteinsaremediatingtheclinicalresponsetoomega3fattyacidsamassspectrometrybasedinvestigationinsubjectsatclinicalhighriskforpsychosis AT schlogelhofermonika evidencethatcomplementandcoagulationproteinsaremediatingtheclinicalresponsetoomega3fattyacidsamassspectrometrybasedinvestigationinsubjectsatclinicalhighriskforpsychosis AT smesnystefan evidencethatcomplementandcoagulationproteinsaremediatingtheclinicalresponsetoomega3fattyacidsamassspectrometrybasedinvestigationinsubjectsatclinicalhighriskforpsychosis AT hickieianb evidencethatcomplementandcoagulationproteinsaremediatingtheclinicalresponsetoomega3fattyacidsamassspectrometrybasedinvestigationinsubjectsatclinicalhighriskforpsychosis AT bergergregore evidencethatcomplementandcoagulationproteinsaremediatingtheclinicalresponsetoomega3fattyacidsamassspectrometrybasedinvestigationinsubjectsatclinicalhighriskforpsychosis AT chenericyh evidencethatcomplementandcoagulationproteinsaremediatingtheclinicalresponsetoomega3fattyacidsamassspectrometrybasedinvestigationinsubjectsatclinicalhighriskforpsychosis AT dehaanlieuwe evidencethatcomplementandcoagulationproteinsaremediatingtheclinicalresponsetoomega3fattyacidsamassspectrometrybasedinvestigationinsubjectsatclinicalhighriskforpsychosis AT niemandorienh evidencethatcomplementandcoagulationproteinsaremediatingtheclinicalresponsetoomega3fattyacidsamassspectrometrybasedinvestigationinsubjectsatclinicalhighriskforpsychosis AT nordentoftmerete evidencethatcomplementandcoagulationproteinsaremediatingtheclinicalresponsetoomega3fattyacidsamassspectrometrybasedinvestigationinsubjectsatclinicalhighriskforpsychosis AT riecherrossleranita evidencethatcomplementandcoagulationproteinsaremediatingtheclinicalresponsetoomega3fattyacidsamassspectrometrybasedinvestigationinsubjectsatclinicalhighriskforpsychosis AT vermaswapna evidencethatcomplementandcoagulationproteinsaremediatingtheclinicalresponsetoomega3fattyacidsamassspectrometrybasedinvestigationinsubjectsatclinicalhighriskforpsychosis AT streetrebekah evidencethatcomplementandcoagulationproteinsaremediatingtheclinicalresponsetoomega3fattyacidsamassspectrometrybasedinvestigationinsubjectsatclinicalhighriskforpsychosis AT thompsonandrew evidencethatcomplementandcoagulationproteinsaremediatingtheclinicalresponsetoomega3fattyacidsamassspectrometrybasedinvestigationinsubjectsatclinicalhighriskforpsychosis AT yungalisonruth evidencethatcomplementandcoagulationproteinsaremediatingtheclinicalresponsetoomega3fattyacidsamassspectrometrybasedinvestigationinsubjectsatclinicalhighriskforpsychosis AT nelsonbarnaby evidencethatcomplementandcoagulationproteinsaremediatingtheclinicalresponsetoomega3fattyacidsamassspectrometrybasedinvestigationinsubjectsatclinicalhighriskforpsychosis AT mcgorrypatrickd evidencethatcomplementandcoagulationproteinsaremediatingtheclinicalresponsetoomega3fattyacidsamassspectrometrybasedinvestigationinsubjectsatclinicalhighriskforpsychosis AT fockingmelanie evidencethatcomplementandcoagulationproteinsaremediatingtheclinicalresponsetoomega3fattyacidsamassspectrometrybasedinvestigationinsubjectsatclinicalhighriskforpsychosis AT ammingergpaul evidencethatcomplementandcoagulationproteinsaremediatingtheclinicalresponsetoomega3fattyacidsamassspectrometrybasedinvestigationinsubjectsatclinicalhighriskforpsychosis AT cotterdavid evidencethatcomplementandcoagulationproteinsaremediatingtheclinicalresponsetoomega3fattyacidsamassspectrometrybasedinvestigationinsubjectsatclinicalhighriskforpsychosis |